Protalix BioTherapeutics, Inc. (FRA:PBDA)

Revenue by Product

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Recombinant Therapeutic Proteins	38.35M
Recombinant Therapeutic Proteins Growth	-19.50%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Global	21.60M
Global Growth	-3.33%
United States	10.16M
United States Growth	-18.08%
Brazil	6.40M
Brazil Growth	-32.29%
Italy	189.00K
Italy Growth	-94.50%